Samsung Biologics– tag –
-
Samsung Biologics Expands CDMO Reach with 60,000L GSK Facility Acquisition and Strategic PolyPeptide Group Buyout
Samsung Biologics South Korea Overview Samsung Biologics significantly bolstered its CDMO capabilities by acquiring a 60,000-liter GSK facility in Maryland, boosting total capacity to 845,000 liters, and agreeing to acquire PolyPeptide G... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Leading CDMOs Lonza, Samsung Biologics, Charles River Laboratories Spearhead Viral Vector Production, Legend Biotech Drives CAR-T Commercialization
GENE ONLINE|News & Opinion. Blog USA Overview Lonza, Samsung Biologics, and Charles River Laboratories are leading the complex viral vector manufacturing essential for scaling cell and gene therapies (CGTs), while Legend Biotech is drivi... -
Cell & Gene Therapy Manufacturing Faces Deepening Bottlenecks: AmplifyBio, Exothera Close; Thermo Fisher Cuts Viral Vector Jobs, but FDA Eases Regulations to Support Growth
Endpoints News Global Overview Despite cell and gene therapies becoming a commercial reality, manufacturing remains the primary bottleneck. The CDMO sector is struggling with overcapacity and underfunding, leading to closures like Amplif... -
Fujifilm Prepares for Patent Cliff with Strategic CDMO Investments; Samsung Biologics Acquires PolyPeptide for $1.8B, Entering Peptide Market
Endpoints News Global Overview The pharmaceutical industry faces a 'patent cliff' with ~$300 billion in branded drug revenues at risk from 2025-2030, driving active deals for portfolio expansion and cost efficiency. Contract Development ... -
Repligen Acquires BioLife Solutions for ~$1.5B, Expanding Cell Therapy Services; Beone Medicines Invests $300M in US Manufacturing Expansion
Endpoints News USA Overview Repligen has announced the acquisition of cell processing service provider BioLife Solutions for approximately $1.5 billion, significantly broadening its capabilities within the cell therapy sector. Concurrent... -
Biopharmaceuticals Contract Manufacturing Market Expands Amid Global Demand: CDMOs Scale Up Capacity
openPR.com Unknown Overview This article provides an overview of a market research report published by openPR.com. The biopharmaceutical contract manufacturing market is growing due to increased demand for biosimilars, expanded investmen... -
Samsung Biologics Acquires PolyPeptide in All-Cash Offer: Accelerating Multi-Modality Strategy and Global Network Expansion
PR Newswire South Korea Overview Samsung Biologics announced an all-cash offer to acquire PolyPeptide, accelerating its multi-modality strategy and expanding its global manufacturing network across the U.S., Europe, and India. This acqui... -
Samsung Biologics Revolutionizes Bioprocess Manufacturing Intelligence by Integrating Digital Twin and AI for Proactive Decision-Making
Samsung Biologics South Korea Overview Samsung Biologics is revolutionizing manufacturing intelligence by advancing a digital bioprocess framework integrating multivariate data analysis (MVDA), predictive modeling, and explainable AI. Th... -
Pharmaceutical CDMO Market Report: Capital Investments and Advanced Therapies Drive Growth
Global Market Insights Global Overview This article provides an overview of the Pharmaceutical CDMO Market research report published by Global Market Insights. The report highlights significant capital investments and major expansions wi...
